Equillium Announces Pricing of Initial Public Offering
Equillium (Nasdaq:EQ), a biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced the pricing of its initial public offering of 4,670,000 shares of common stock at a public offering price of $14.00 per share. As quoted in the press release: … Continued
Equillium (Nasdaq:EQ), a biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced the pricing of its initial public offering of 4,670,000 shares of common stock at a public offering price of $14.00 per share.
As quoted in the press release:
Equillium anticipates total gross proceeds of approximately $65.4 million, before deducting underwriting discounts and commissions and other offering expenses. All shares of common stock are being offered by Equillium. The shares are expected to begin trading on the Nasdaq Global Market on October 12, 2018 under the ticker symbol “EQ.” In addition, Equillium has granted the underwriters a 30-day option to purchase up to an additional 700,500 shares of common stock at the initial public offering price.
Jefferies LLC, Leerink Partners LLC and Stifel, Nicolaus & Company, Incorporated are acting as joint book-running managers for the offering.
